School of Medicine
Showing 1-31 of 31 Results
-
Israt Alam
Senior Research Scientist-Basic Life, Rad/Molecular Imaging Program at Stanford
BioResearch Focus and interests: Molecular Imaging, PET, Immuno-Oncology, Graft versus Host Disease, CAR T cells
Dr. Israt Alam is a Senior Scientist in the Radiology Department at Stanford University. She trained in Prof. Sanjiv Sam Gambhir's lab and transitioned to Dr. Michelle James' lab in 2021. Her research focuses on studying lymphocyte activation with the motivation of developing non-invasive imaging tools, to monitor immune dynamics in response to cancer immunotherapy and in immunopathology. Her work has supported the clinical translation of several nuclear imaging agents (small molecules and a biologic) for early detection of cancer and prediction of treatment response. She has also worked on several biomarker detection platforms for early disease detection. She is currently co-chair of the "Imaging in cell and immune therapies" (ICIT) interest group for the World Molecular Imaging Society (WMIS).
Appointments:
-Senior Research Scientist, James Lab, Department of Radiology, Stanford
-Life Sciences Research Associate, Gambhir Lab, Department of Radiology, Stanford
-Post-Doctoral Scholar, Gambhir Lab, Department of Radiology, Stanford
-Visiting Researcher /Churchill Travel Fellow in the Plateforme d'imagerie dynamique lab of Prof. Spencer Shorte, Pasteur Institute, Paris
-Science Education Consultant: United Nations Educational, Science and Cultural Organization (UNESCO), Paris
-Science Education Intern: United Nations Educational, Science and Cultural Organization (UNESCO), Paris -
Vikram S Bajaj
Adjunct Professor, Rad/Molecular Imaging Program at Stanford
BioAdj. Professor, Stanford Radiology.
Managing Director, Foresite Capital Management
Co-Founder/CEO, Foresite Labs
Previous:
Chief Scientific Officer, GRAIL
Chief Scientific Officer and Co-Founder, Verily (Google Life Sciences) -
Edwin Chang
Director, Small Animal Imaging Facility at Porter Drive, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordDirector, SCI3@Porter or the Canary Core Preclinical Imaging Facility at Stanford
-
Ka Chun Ho
Lab Assistant I, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordLab Assistant I - Stanford University, Cyclotron & Radiochemistry Facility
-
Mausam Kalita
Temp - Non-Exempt, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordSenior Research Scientist:
1) cold chemical synthesis— Synthesis of the 12C and 19F- HPLC standards and precursors for 11C- and 18F- labeling
2) radiosynthesis— Introduction of 11C or 18F radioisotopes into small molecules to develop novel PET tracers, that can track activated myeloid cells in neurodegenerative diseases
3) radiometal labeling— 64Cu and 89Zr labeling of monoclonal antibodies that target immune receptors
4) clinical translation— To follow FDA guidelines for translating preclinically validated tracers into humans in the cyclotron and radiochemistry facility (CRF) of the Stanford University -
Jeffrey Howard Kleck
Adjunct Professor, Rad/Molecular Imaging Program at Stanford
BioJeff is an Adjunct Professor at Stanford University and a leader in the Silicon Valley tech venture community. He is an established technology and software entrepreneur who has built several ventures from concept to market leader. Jeff has served as Founder, CEO, and Chairman, and has taken his ventures public on the NASDAQ and unified them into far-reaching commercial corporations.
Jeff is a Managing Partner of Elevens, a strategic advisory designed to harness some of the foremost AI minds on the planet to accelerate breakthrough ventures in health-tech, med-tech, bio-tech, and pharma-tech. Elevens is based in Silicon Valley and can be found at www.elevens.ai.
Jeff has served as a Highly Qualified Expert (HQE) for the United States Government as a Director responsible for delivering transformational and strategic capabilities to strengthen national security by accelerating the adoption of innovative and commercial technologies.
Jeff has participated as a visiting scientist at two national laboratories, including Lawrence Berkeley National Laboratory and Los Alamos National Laboratory, and as an Adjunct Professor at the University of California Los Angeles (UCLA).
Jeff is formally educated in several engineering, medical applied science, and technology disciplines, and holds a PhD in Biomedical Physics from UCLA, an MS in Engineering Management from Stanford University, an MS in Nuclear Engineering from Texas A&M University, and a BS in Nuclear Engineering from Texas A&M University.
The industry profile for Jeff can be found at www.linkedin.com/in/jeff-kleck-a000299/ and the commercial profile for Elevens can be found at https://www.linkedin.com/company/82564221/ -
Jason Thanh Lee
Deputy Director, Molecular Imaging Program, Rad/Molecular Imaging Program at Stanford
BioBiomedical imaging scientist in preclinical molecular and nuclear imaging, particularly employing PET, CT and optical techniques. Applications include therapeutic development, oncology, immunotherapy, neuroscience, and molecular biology. Active in translational diagnostics research and development. Lead a scientific team and skilled in project management with a portfolio of academic and pharmaceutical/biotechnology partners. Broad foundation in molecular biology assays and in vivo disease models.
-
Noeen Malik, PhD
Physical Science Research Scientist, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordResearch Scientist
CRF, MIPS, Stanford School of Medicine, Stanford | January 2022 — Present
Responsibilities:
• R & D of radiopharmaceuticals for oncology and neuroscience
• Industrial collaborations
• Market strategic report for theragnostic-isotopes for Nextgen Cyclotron project
• CRF website development project
https://cyclotron.stanford.edu/ -
Aaron Mayer
Casual - Non-Exempt, Rad/Molecular Imaging Program at Stanford
BioImmunotherapy has the potential to become the new paradigm of cancer treatment. While anatomic imaging has been the gold standard to monitor treatment efficacy based upon decreases in tumor size, patients treated with immunotherapies often present with a period of apparent tumor growth before prolonged regression. Due to the high cost and delayed response time, there exists a compelling need to accurately predict which patients are most likely to benefit from immune based treatment strategies. Aaron hopes to develop a molecular imaging toolkit including novel software, hardware, and biological wetware to improve monitoring of cancer immunotherapies in the clinic. He is advised on this project by Dr. Sam Gambhir. Aaron brings with him experience in multi-modality molecular imaging of cancer from his time spent under the mentorship of Dr. Efstathios Karathanasis and Dr. Mark Griswold at the Case Center for Imaging Research in Cleveland, Ohio. After graduating from CWRU, Aaron spent a year in Switzerland as a Fulbright Fellow at the Ecole Polytechnique Federale de Lausanne (EPFL) where, with the guidance of Dr. Melody Swartz and Dr. Jeffrey Hubbell, he utilized imaging tools to better understand the mechanisms of therapeutic cancer vaccines.
-
Arutselvan Natarajan
Senior Research Scientist - Basic Life, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordSenior Scientist
-
Raheleh Roudi
Basic Life Research Scientist, Rad/Molecular Imaging Program at Stanford
BioRaheleh Roudi is a research scientist in the Department of Radiology at Stanford University. Dr. Roudi trained at the Iran University of Medical Sciences, Iran. She worked as an Assistant Professor at the Iran University of Medical Sciences, Iran from 2015 to 2019, before coming to the United States. During this time, Dr. Roudi worked on several projects which have led to successful collaborations with the Karolinska Institute; Charite Universitatsmedizin Berlin; Oslo University Hospital; National University of Singapore; Shanghai University of Traditional Chinese Medicine and University of Brescia, among other internationally recognized institutions.
Dr. Roudi was a visiting scientist in the University of Texas at San Antonio and then appointed as a postdoctoral associate at the University of Minnesota for one year, before joining Stanford University in 2022.
Her research interest focuses on the molecular oncology and immunotherapies of solid tumors and she published more than 40 peer reviewed papers.